Anticoagulation in the management of non-ST-segment elevation acute coronary syndrome

Paul P. Dobesh, Toby C. Trujillo

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

There are currently over 1 million patients admitted to hospitals in the United States with the diagnosis of non-ST-segment elevation acute coronary syndrome (NSTE ACS). Due to the significant morbidity and mortality associated with NSTE ACS, appropriate use of the numerous medications employed is critical in ensuring optimal outcomes. Because atherosclerotic plaque rupture and thrombus formation are the central pathophysiologic process in patients with NSTE ACS, it is important to utilize effective and safe combinations of antiplatelet and anticoagulant drug therapy. There are a number of different anticoagulant agents available for use in patients with NSTE ACS, but it is essential to have an in-depth knowledge of the setting in which these agents have been investigated, what current consensus guidelines recommend, as well as an appreciation for the treatment approach and philosophy of the institution for management of patients with NSTE ACS. In this review manuscript, the reader will find an evaluation of the current guidelines concerning the use of anticoagulant therapy in patients with NSTE ACS, as well as a detailed examination of the literature with critical analysis on issues that should be considered when deciding on the appropriate implementation of anticoagulant therapy in protocols for NSTE ACS patients.

Original languageEnglish (US)
Pages (from-to)324-334
Number of pages11
JournalJournal of Pharmacy Practice
Volume23
Issue number4
DOIs
StatePublished - Aug 2010

Fingerprint

Acute Coronary Syndrome
Anticoagulants
Guidelines
Manuscripts
Platelet Aggregation Inhibitors
Atherosclerotic Plaques
Rupture
Thrombosis
Therapeutics
Morbidity
Drug Therapy
Mortality

Keywords

  • acute coronary syndrome
  • anticoagulation
  • bivalirudin
  • cardiology
  • coronary artery disease
  • enoxaparin
  • fondaparinux
  • low-molecular-weight heparin
  • unfractionated heparin

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Anticoagulation in the management of non-ST-segment elevation acute coronary syndrome. / Dobesh, Paul P.; Trujillo, Toby C.

In: Journal of Pharmacy Practice, Vol. 23, No. 4, 08.2010, p. 324-334.

Research output: Contribution to journalReview article

@article{82ed1818e74741de8478ec29f4e867f4,
title = "Anticoagulation in the management of non-ST-segment elevation acute coronary syndrome",
abstract = "There are currently over 1 million patients admitted to hospitals in the United States with the diagnosis of non-ST-segment elevation acute coronary syndrome (NSTE ACS). Due to the significant morbidity and mortality associated with NSTE ACS, appropriate use of the numerous medications employed is critical in ensuring optimal outcomes. Because atherosclerotic plaque rupture and thrombus formation are the central pathophysiologic process in patients with NSTE ACS, it is important to utilize effective and safe combinations of antiplatelet and anticoagulant drug therapy. There are a number of different anticoagulant agents available for use in patients with NSTE ACS, but it is essential to have an in-depth knowledge of the setting in which these agents have been investigated, what current consensus guidelines recommend, as well as an appreciation for the treatment approach and philosophy of the institution for management of patients with NSTE ACS. In this review manuscript, the reader will find an evaluation of the current guidelines concerning the use of anticoagulant therapy in patients with NSTE ACS, as well as a detailed examination of the literature with critical analysis on issues that should be considered when deciding on the appropriate implementation of anticoagulant therapy in protocols for NSTE ACS patients.",
keywords = "acute coronary syndrome, anticoagulation, bivalirudin, cardiology, coronary artery disease, enoxaparin, fondaparinux, low-molecular-weight heparin, unfractionated heparin",
author = "Dobesh, {Paul P.} and Trujillo, {Toby C.}",
year = "2010",
month = "8",
doi = "10.1177/0897190010366931",
language = "English (US)",
volume = "23",
pages = "324--334",
journal = "Journal of Pharmacy Practice",
issn = "0897-1900",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Anticoagulation in the management of non-ST-segment elevation acute coronary syndrome

AU - Dobesh, Paul P.

AU - Trujillo, Toby C.

PY - 2010/8

Y1 - 2010/8

N2 - There are currently over 1 million patients admitted to hospitals in the United States with the diagnosis of non-ST-segment elevation acute coronary syndrome (NSTE ACS). Due to the significant morbidity and mortality associated with NSTE ACS, appropriate use of the numerous medications employed is critical in ensuring optimal outcomes. Because atherosclerotic plaque rupture and thrombus formation are the central pathophysiologic process in patients with NSTE ACS, it is important to utilize effective and safe combinations of antiplatelet and anticoagulant drug therapy. There are a number of different anticoagulant agents available for use in patients with NSTE ACS, but it is essential to have an in-depth knowledge of the setting in which these agents have been investigated, what current consensus guidelines recommend, as well as an appreciation for the treatment approach and philosophy of the institution for management of patients with NSTE ACS. In this review manuscript, the reader will find an evaluation of the current guidelines concerning the use of anticoagulant therapy in patients with NSTE ACS, as well as a detailed examination of the literature with critical analysis on issues that should be considered when deciding on the appropriate implementation of anticoagulant therapy in protocols for NSTE ACS patients.

AB - There are currently over 1 million patients admitted to hospitals in the United States with the diagnosis of non-ST-segment elevation acute coronary syndrome (NSTE ACS). Due to the significant morbidity and mortality associated with NSTE ACS, appropriate use of the numerous medications employed is critical in ensuring optimal outcomes. Because atherosclerotic plaque rupture and thrombus formation are the central pathophysiologic process in patients with NSTE ACS, it is important to utilize effective and safe combinations of antiplatelet and anticoagulant drug therapy. There are a number of different anticoagulant agents available for use in patients with NSTE ACS, but it is essential to have an in-depth knowledge of the setting in which these agents have been investigated, what current consensus guidelines recommend, as well as an appreciation for the treatment approach and philosophy of the institution for management of patients with NSTE ACS. In this review manuscript, the reader will find an evaluation of the current guidelines concerning the use of anticoagulant therapy in patients with NSTE ACS, as well as a detailed examination of the literature with critical analysis on issues that should be considered when deciding on the appropriate implementation of anticoagulant therapy in protocols for NSTE ACS patients.

KW - acute coronary syndrome

KW - anticoagulation

KW - bivalirudin

KW - cardiology

KW - coronary artery disease

KW - enoxaparin

KW - fondaparinux

KW - low-molecular-weight heparin

KW - unfractionated heparin

UR - http://www.scopus.com/inward/record.url?scp=77956251727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956251727&partnerID=8YFLogxK

U2 - 10.1177/0897190010366931

DO - 10.1177/0897190010366931

M3 - Review article

C2 - 21507832

AN - SCOPUS:77956251727

VL - 23

SP - 324

EP - 334

JO - Journal of Pharmacy Practice

JF - Journal of Pharmacy Practice

SN - 0897-1900

IS - 4

ER -